Evidence map›Paper›PMID 25348620›Full record

ArticleThe pharmacogenomics journal2015

Frequent intragenic rearrangements of DPYD in colorectal tumours.

A B P van Kuilenburg, M-C Etienne-Grimaldi, A Mahamat, J Meijer, P Laurent-Puig, S Olschwang, M-P Gaub, R C M Hennekam, D Benchimol, S Houry and 9 more

Open access · bronzeAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in The pharmacogenomics journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 13 institutions in 2 countries.

A B P van KuilenburgDepartment of Clinical Chemistry and Pediatrics, Academic Medical Center, University of Amsterdam, Emma Children's Hospital, Amsterdam, The Netherlands.
M-C Etienne-GrimaldiCentre Antoine Lacassagne, Laboratoire d'Oncopharmacologie, Nice cedex 2, France.
A MahamatUnité de cancérologie digestive Hôpital Archet II, Nice cedex, France.
J MeijerDepartment of Clinical Chemistry and Pediatrics, Academic Medical Center, University of Amsterdam, Emma Children's Hospital, Amsterdam, The Netherlands.
P Laurent-PuigHôpital Georges Pompidou, Paris, France.
S OlschwangINSERM UMR_S910, Marseille, France.
M-P GaubHôpitaux Universitaires de Strasbourg, Strasbourg, France.
R C M HennekamDepartment of Clinical Chemistry and Pediatrics, Academic Medical Center, University of Amsterdam, Emma Children's Hospital, Amsterdam, The Netherlands.
D BenchimolHôpital de L'Archet-CHU de Nice, Nice, France.
S HouryHôpital Tenon, Université Pierre et Marie Curie, Paris, France.
C LetoublonDepartment of Surgery, University Hospital and Joseph Fourier University, Grenoble, France.
F-N GillyUniversité Claude Bernard Lyon 1, Pierre bénite cedex, France.
D PezetCHU Clermont Ferrand, Clermont Ferrand Cedex 1, France.
T AndreDepartment of medical Oncology, Saint Antoine Hospital, Paris, France.
J-L FaucheronDepartment of Surgery, University Hospital and Joseph Fourier University, Grenoble, France.
A Abderrahim-FerkouneDepartment of Surgery, CHU de Nice, Nice, France.
R VijzelaarMRC-Holland, Amsterdam, The Netherlands.
B PradereCentre Hospitalier Universitaire de Toulouse, Université Toulouse III Paul Sabatier, Toulouse, France.
G MilanoCentre Antoine Lacassagne, Laboratoire d'Oncopharmacologie, Nice cedex 2, France.
Centre Antoine Lacassagne · FRHôpital l'Archet · FRUniversité Joseph Fourier · FRCentre Hospitalier Universitaire de Clermont-Ferrand · FRCentre Hospitalier Universitaire de Nice · FRCentre Hospitalier Universitaire de Toulouse · FRHôpital Européen · FRHôpital Tenon · FRHôpitaux Universitaires de Strasbourg · FRInserm · FRMRC Holland (Netherlands) · NLSorbonne Université · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dihydropyrimidine dehydrogenase is a crucial enzyme for the degradation of 5-fluorouracil (5FU). DPYD, which encodes dihydropyrimidine dehydrogenase, is prone to acquire genomic rearrangements because of the presence of an intragenic fragile site FRA1E. We evaluated DPYD copy number variations (CNVs) in a prospective series of 242 stage I-III colorectal tumours (including 87 patients receiving 5FU-based treatment). CNVs in one or more exons of DPYD were detected in 27% of tumours (deletions or amplifications of one or more DPYD exons observed in 17% and 10% of cases, respectively). A significant relationship was observed between the DPYD intragenic rearrangement status and dihydropyrimidine dehydrogenase (DPD) mRNA levels (both at the tumour level). The presence of somatic DPYD aberrations was not associated with known prognostic or predictive biomarkers, except for LOH of chromosome 8p. No association was observed between DPYD aberrations and patient survival, suggesting that assessment of somatic DPYD intragenic rearrangement status is not a powerful biomarker to predict the outcome of 5FU-based chemotherapy in patients with colorectal cancer.

Indexed as

AdultAgedAged, 80 and overAntimetabolites, AntineoplasticBiomarkers, TumorColorectal NeoplasmsDihydrouracil Dehydrogenase (NADP)DNA Copy Number VariationsExonsFemaleFluorouracilGene RearrangementHumansMaleMiddle AgedPrognosisAntimetabolites, AntineoplasticBiomarkers, TumorDihydrouracil Dehydrogenase (NADP)FluorouracilRNA, Messenger

Identifiers

PMID25348620
OpenAlexW1996774564

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.